Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 12/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.57 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.55 |
| ▸ | LTA4H | P09960 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.50 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.50 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.50 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.50 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24324832 | 0.87 | SPHK1 (0.64) | SPHK1SPHK2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14349974 | 0.86 | SPHK1 (0.56) | SPHK1SPHK2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11646041 | 0.83 | SPHK1 (0.60) | SPHK1SPHK2LTA4HNPC1RAB9A | |
| SCHEMBL11644855 | 0.83 | SPHK1 (0.60) | SPHK1SPHK2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17823132 | 0.83 | TAAR1 (0.60) | SPHK1TAAR1SPHK2LTA4HSMN1; SMN2 | |
| SCHEMBL19358957 | 0.83 | TAAR1 (0.60) | SPHK1TAAR1LTA4HSMN1; SMN2 | |
| SCHEMBL17823130 | 0.83 | TAAR1 (0.60) | SPHK1TAAR1SPHK2LTA4HSMN1; SMN2 | |
| SCHEMBL5551584 | 0.82 | SPHK1 (0.51) | SPHK1SPHK2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11647047 | 0.82 | CA12 (0.61) | SPHK1SPHK2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20715719 | 0.81 | SPHK1 (0.59) | SPHK1SPHK2S1PR1S1PR3S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759785-B2 | Compounds | Enterprise Therapeutics Limited (GB) | 2020-09-01 | — | — | US | disclosed |
| EP-3472154-B1 | COMPOUNDS | ENTERPRISE THERAPEUTICS LTD (GB) | 2020-08-12 | — | — | EP | disclosed |
| US-20190233402-A1 | COMPOUNDS | Enterprise Therapeutics Limited (GB) | 2019-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233402-A1 | COMPOUNDS | CFTR, NHERF1, SCNN1A | SPHK1 2858/4885TAAR1 1334/4885SPHK2 3409/4885 |
| US-10759785-B2 | Compounds | CFTR, NHERF1, SCNN1A | SPHK1 2858/4885TAAR1 1334/4885SPHK2 3409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.